Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, Okpechi I et al (2015) Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet 385(9981):1975–1982

Article  PubMed  Google Scholar 

Samokhvalova NA, Romanchishen AF, Gerasimchuk RP, Grinev KM, Zemchenkov A (2007) Secondary hyperparathyroidism: incidence, clinical presentations, treatment. Vestn Khir Im I I Grek 166(5):78–81

CAS  PubMed  Google Scholar 

Adler JT, Sippel RS, Chen H (2010) New trends in parathyroid surgery. Curr Probl Surg 47(12):958–1017

Article  PubMed  Google Scholar 

Tentori F, Wang M, Bieber BA, Karaboyas A, Li Y, Jacobson SH et al (2015) Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clin J Am Soc Nephrol 10(1):98–109

Article  CAS  PubMed  Google Scholar 

Bureo JC, Arevalo JC, Anton J, Adrados G, Jimenez Morales JL, Robles NR et al (2015) Prevalence of secondary hyperparathyroidism in patients with stage 3 and 4 chronic kidney disease seen in internal medicine. Endocrinol Nutr 62(7):300–305

Article  PubMed  Google Scholar 

Massimetti C, Imperato G, Feriozzi S (2019) Correction of secondary hyperparathyroidism with paricalcitol in renal transplant improves left ventricular hypertrophy. G Ital Nefrol 36(1)

Di Lullo L, Floccari F, Polito P (2011) Right ventricular diastolic function in dialysis patients could be affected by vascular access. Nephron Clin Pract 118(3):c257–c261

Article  PubMed  Google Scholar 

Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Stancanelli B et al (2004) Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int 65(4):1492–1498

Article  PubMed  Google Scholar 

Baigent C, Herrington WG, Coresh J, Landray MJ, Levin A, Perkovic V et al (2017) Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 92(2):297–305

Article  PubMed  PubMed Central  Google Scholar 

Ketteler M, Elder GJ, Evenepoel P, Ix JH, Jamal SA, Lafage-Proust MH et al (2015) Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: a commentary from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney Int 87(3):502–528

Article  PubMed  Google Scholar 

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612

Article  PubMed  PubMed Central  Google Scholar 

Clerc OF, Kaufmann BP, Possner M, Liga R, Vontobel J, Mikulicic F et al (2017) Long-term prognostic performance of low-dose coronary computed tomography angiography with prospective electrocardiogram triggering. Eur Radiol 27(11):4650–4660

Article  PubMed  Google Scholar 

Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R (1990) Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 15(4):827–832

Article  CAS  PubMed  Google Scholar 

Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L et al (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 28(1):1–39 e14

Article  PubMed  Google Scholar 

National Kidney Foundation (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42(4 Suppl 3):S1–S201

Google Scholar 

GBD 2015 Mortality and Causes of Death Collaborators (2016) Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388(10053):1459–1544

Article  Google Scholar 

Xu H, Peng W, Yang Z, Zhang Y, Xia C, Li Z et al (2021) The association of secondary hyperparathyroidism and myocardial damages in hemodialysis end-stage renal disease patients: assessed by cardiovascular magnetic resonance native T1 mapping. J Cardiovasc Magn Reson 23(1):23

Article  PubMed  PubMed Central  Google Scholar 

Hara S, Ubara Y, Arizono K, Ikeguchi H, Katori H, Yamada A et al (1995) Relation between parathyroid hormone and cardiac function in long-term hemodialysis patients. Miner Electrolyte Metab 21(1-3):72–76

CAS  PubMed  Google Scholar 

Mattioli AV, Zennaro M, Bonatti S, Bonetti L, Mattioli G (2004) Regression of left ventricular hypertrophy and improvement of diastolic function in hypertensive patients treated with telmisartan. Int J Cardiol 97(3):383–388

Article  CAS  PubMed  Google Scholar 

Devereux RB, Palmieri V, Liu JE, Wachtell K, Bella JN, Boman K et al (2002) Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study. J Hypertens 20(7):1445–1450

Article  CAS  PubMed  Google Scholar 

Jula AM, Karanko HM (1994) Effects on left ventricular hypertrophy of long-term nonpharmacological treatment with sodium restriction in mild-to-moderate essential hypertension. Circulation 89(3):1023–1031

Article  CAS  PubMed  Google Scholar 

Culleton BF, Walsh M, Klarenbach SW, Mortis G, Scott-Douglas N, Quinn RR et al (2007) Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA 298(11):1291–1299

Article  CAS  PubMed  Google Scholar 

Covic A, Mardare NG, Ardeleanu S, Prisada O, Gusbeth-Tatomir P, Goldsmith DJ (2006) Serial echocardiographic changes in patients on hemodialysis: an evaluation of guideline implementation. J Nephrol 19(6):783–793

CAS  PubMed  Google Scholar 

Custodio MR, Koike MK, Neves KR, dos Reis LM, Graciolli FG, Neves CL et al (2012) Parathyroid hormone and phosphorus overload in uremia: impact on cardiovascular system. Nephrol Dial Transplant 27(4):1437–1445

Article  CAS  PubMed  Google Scholar 

Schluter KD, Piper HM (1998) Left ventricular hypertrophy and parathyroid hormone: a causal connection? Cardiovasc Res 39(2):523–524

CAS  PubMed  Google Scholar 

Schluter KD, Piper HM (1998) Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Cardiovasc Res 37(1):34–41

Article  CAS  PubMed  Google Scholar 

Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T et al (2011) FGF23 induces left ventricular hypertrophy. J Clin Invest 121(11):4393–4408

Article  CAS  PubMed  PubMed Central  Google Scholar 

Randon RB, Rohde LE, Comerlato L, Ribeiro JP, Manfro RC (2005) The role of secondary hyperparathyroidism in left ventricular hypertrophy of patients under chronic hemodialysis. Braz J Med Biol Res 38(9):1409–1416

Article  CAS  PubMed  Google Scholar 

Drueke T, Fauchet M, Fleury J, Lesourd P, Toure Y, Le Pailleur C et al (1980) Effect of parathyroidectomy on left-ventricular function in haemodialysis patients. Lancet 1(8160):112–114

Article  CAS  PubMed  Google Scholar 

Investigators ET, Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J et al (2012) Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367(26):2482–2494

Article  Google Scholar 

Wheeler DC, London GM, Parfrey PS, Block GA, Correa-Rotter R, Dehmel B et al (2014) Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the evaluation of cinacalcet hcl therapy to lower cardiovascular events (EVOLVE) trial. J Am Heart Assoc 3(6):e001363

Article  PubMed  PubMed Central  Google Scholar 

Choi SR, Lim JH, Kim MY, Hong YA, Chung BH, Chung S et al (2012) Cinacalcet improves endothelial dysfunction and cardiac hypertrophy in patients on hemodialysis with secondary hyperparathyroidism. Nephron Clin Pract 122(1-2):1–8

Article  CAS  PubMed  Google Scholar 

Dorr K, Kammer M, Reindl-Schwaighofer R, Lorenz M, Prikoszovich T, Marculescu R et al (2021) Randomized trial of etelcalcetide for cardiac hypertrophy in hemodialysis. Circ Res 128(11):1616–1625

Article